Published in Int J Biol Sci on April 26, 2011
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57
MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One (2012) 1.42
Molecular biology of liver cancer stem cells. Liver Cancer (2014) 1.41
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta (2012) 1.26
Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal (2013) 1.24
Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology (2012) 1.21
Downregulation of miR-200a induces EMT phenotypes and CSC-like signatures through targeting the β-catenin pathway in hepatic oval cells. PLoS One (2013) 1.05
Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther (2013) 1.02
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol (2015) 1.01
Immune modulatory function of abundant immune-related microRNAs in microvesicles from bovine colostrum. Protein Cell (2013) 0.97
Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J Gastrointest Oncol (2012) 0.93
Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicol Sci (2013) 0.91
Wnt inhibitory factor 1 suppresses cancer stemness and induces cellular senescence. Cell Death Dis (2014) 0.86
5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. Int J Biol Sci (2015) 0.85
Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma. Gastroenterol Res Pract (2013) 0.84
Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol (2016) 0.83
8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin. World J Gastroenterol (2013) 0.82
A novel in vitro model for cancer stem cell culture using ectopically expressed piwil2 stable cell line. Cell J (2013) 0.81
Elimination of cancer stem-like "side population" cells in hepatoma cell lines by chinese herbal mixture "tien-hsien liquid". Evid Based Complement Alternat Med (2012) 0.81
Function and clinical potential of microRNAs in hepatocellular carcinoma. Oncol Lett (2015) 0.81
Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention. Mol Cancer (2017) 0.80
Role of liver stem cells in hepatocarcinogenesis. World J Stem Cells (2014) 0.79
BMI-1, a promising therapeutic target for human cancer. Oncol Lett (2015) 0.79
A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy. EJNMMI Res (2014) 0.79
Metabolic stress induces a Wnt-dependent cancer stem cell-like state transition. Cell Death Dis (2015) 0.79
High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells. Chem Biol Drug Des (2013) 0.78
Curcumin regulates hepatoma cell proliferation and apoptosis through the Notch signaling pathway. Int J Clin Exp Med (2014) 0.78
Proliferation versus regeneration: the good, the bad and the ugly. Front Physiol (2014) 0.78
CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment. Oncotarget (2016) 0.77
Composite fatty acid ether amides suppress growth of liver cancer cells in vitro and in an in vivo allograft mouse model. Cell Oncol (Dordr) (2013) 0.76
Cancer stem cells in hepatocellular carcinomas. Indian J Med Res (2015) 0.75
Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population. Oncotarget (2016) 0.75
Expression and activation of EGFR and STAT3 during the multistage carcinogenesis of intrahepatic cholangiocarcinoma induced by 3'-methyl-4 dimethylaminoazobenzene in rats. J Toxicol Pathol (2015) 0.75
Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting. Front Pharmacol (2017) 0.75
Hedgehog signalling pathway: carcinogenesis and targeted therapy. Iran J Cancer Prev (2013) 0.75
Hepatitis B virus X protein promotes the stem-like properties of OV6(+) cancer cells in hepatocellular carcinoma. Cell Death Dis (2017) 0.75
Effect of Over-Expression of Zinc-Finger Protein (ZFX) on Self-Renewal and Drug-Resistance of Hepatocellular Carcinoma. Med Sci Monit (2016) 0.75
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. PLoS One (2015) 0.75
Zinc finger protein X-linked promotes expansion of EpCAM(+) cancer stem-like cells in hepatocellular carcinoma. Mol Oncol (2017) 0.75
Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma. Target Oncol (2017) 0.75
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Notch signaling: cell fate control and signal integration in development. Science (1999) 28.83
The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol (2004) 24.63
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Wnt signalling in stem cells and cancer. Nature (2005) 19.26
Hedgehog signaling in animal development: paradigms and principles. Genes Dev (2001) 14.75
Selective blockade of microRNA processing by Lin28. Science (2008) 14.39
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature (2003) 14.35
Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol (2006) 13.12
The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA. Cell (1997) 12.87
Liver regeneration. Science (1997) 12.80
TGFbeta signaling in growth control, cancer, and heritable disorders. Cell (2000) 12.38
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 11.94
A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 10.36
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature (2009) 9.15
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta (2003) 7.85
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
Stem cells and cancer; the polycomb connection. Cell (2004) 7.43
Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 6.88
Heterochronic mutants of the nematode Caenorhabditis elegans. Science (1984) 6.85
A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A (2004) 6.84
Liver regeneration. J Cell Physiol (2007) 6.69
Asymmetric cell divisions promote stratification and differentiation of mammalian skin. Nature (2005) 6.67
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb. Cell (2000) 6.08
Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology (2007) 5.75
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
Notch signalling regulates stem cell numbers in vitro and in vivo. Nature (2006) 5.49
Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol (2003) 5.40
The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell (2009) 5.33
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet (2000) 5.26
The Hedgehog response network: sensors, switches, and routers. Science (2004) 5.20
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell (2004) 4.98
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature (2004) 4.82
A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg (2010) 4.75
Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology (2006) 4.61
The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A (2007) 4.52
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell (2001) 4.32
WNT signaling pathway and stem cell signaling network. Clin Cancer Res (2007) 4.24
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res (2005) 4.21
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Human hepatic stem cells from fetal and postnatal donors. J Exp Med (2007) 4.15
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Gene (2006) 4.13
Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol (2009) 4.05
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 4.00
The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene (2010) 4.00
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene (2007) 3.96
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A (2009) 3.76
CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer (2007) 3.65
BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst (2006) 3.61
CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest (2010) 3.60
Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer (2008) 3.56
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51
Shh and Gli3 are dispensable for limb skeleton formation but regulate digit number and identity. Nature (2002) 3.47
Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium (2005) 3.46
Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun (2006) 3.35
The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res (2009) 3.25
Sonic Hedgehog-induced activation of the Gli1 promoter is mediated by GLI3. J Biol Chem (1999) 3.25
Fundamental concepts of the angiogenic process. Curr Mol Med (2003) 3.16
Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology (2004) 3.09
Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev (2002) 3.06
Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci U S A (2008) 2.98
MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology (2008) 2.88
miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell (2010) 2.87
Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology (2001) 2.73
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol (2009) 2.69
Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene (2006) 2.65
Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res (2007) 2.63
Vertebrate hairy and Enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning. Oncogene (2001) 2.55
Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer (2010) 2.54
Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol (2005) 2.52
Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene (2006) 2.49
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
The sonic hedgehog-patched-gli pathway in human development and disease. Am J Hum Genet (2000) 2.42
Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol (1999) 2.41
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology (2008) 2.40
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Cancer stem cells and self-renewal. Clin Cancer Res (2010) 2.37
Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer. Curr Opin Cell Biol (1998) 2.34
Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells. J Hepatol (2003) 2.31
Angiogenesis and hepatocellular carcinoma. J Hepatol (2004) 2.25
The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology (2006) 2.18
Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. Science (2003) 2.16
Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene (2002) 2.16
Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology (2008) 2.12
Epidemiology of hepatocellular carcinoma. Clin Liver Dis (2001) 2.06
Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist (2006) 2.05
Cytokines, STATs and liver disease. Cell Mol Immunol (2005) 2.04
A Wnt signaling pathway controls hox gene expression and neuroblast migration in C. elegans. Development (1999) 2.03
Human hepatic stem cell and maturational liver lineage biology. Hepatology (2011) 1.99
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell (2011) 2.73
Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res (2007) 2.63
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol (2005) 2.15
Cancer stem cells in the development of liver cancer. J Clin Invest (2013) 2.06
The role of cytokines in hepatocellular carcinoma. J Leukoc Biol (2006) 1.75
Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res (2007) 1.73
Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology (2013) 1.73
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology (2013) 1.63
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2013) 1.51
Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol (2012) 1.46
Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology (2004) 1.41
Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol (2010) 1.41
Nucleophosmin and human cancer. Cancer Detect Prev (2006) 1.29
Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology (2010) 1.28
Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology (2013) 1.27
New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biol Ther (2009) 1.23
The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J Biol Chem (2002) 1.22
Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis (2003) 1.13
Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res (2013) 1.09
Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci (2011) 1.08
Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer (2010) 1.05
A Yin-Yang balancing act of the lin28/let-7 link in tumorigenesis. J Hepatol (2010) 1.03
SAGE transcript profiles of normal primary human hepatocytes expressing oncogenic hepatitis B virus X protein. FASEB J (2002) 1.01
Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer (2010) 1.00
Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res (2010) 0.99
microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer (2012) 0.97
Mechanisms of inactivation of hepatitis a virus by chlorine. Appl Environ Microbiol (2002) 0.92
Modulation of miR-29 expression by α-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology (2014) 0.91
Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes. Mol Med (2006) 0.90
Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatology (2015) 0.89
Future of molecular profiling of human hepatocellular carcinoma. Future Oncol (2007) 0.89
Translating the metastasis paradigm from scientific theory to clinical oncology. Clin Cancer Res (2009) 0.89
Mechanisms of inactivation of hepatitis A virus in water by chlorine dioxide. Water Res (2004) 0.88
Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses. J Immunol (2012) 0.87
Power play: scoring our goals for liver cancer with better GWAS study design. J Hepatol (2010) 0.82
microRNA Regulation and Its Consequences in Cancer. Curr Pathobiol Rep (2012) 0.82
Identification of cancer stem cell-related microRNAs in hepatocellular carcinoma. Methods Mol Biol (2012) 0.80
Transforming the microenvironment: a trick of the metastatic cancer cell. Cancer Cell (2012) 0.78
Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. Int J Biol Sci (2013) 0.78
iSubgraph: integrative genomics for subgroup discovery in hepatocellular carcinoma using graph mining and mixture models. PLoS One (2013) 0.78
At the cancer steering wheel: defining key genomic drivers of liver cancer with next generation sequencing. J Hepatol (2012) 0.75
Identification of genomic functional hotspots with copy number alteration in liver cancer. EURASIP J Bioinform Syst Biol (2013) 0.75
A phase II clinical trial with cytotropic heterogeneous molecular lipids (CHML) for patients with hepatic malignancies. Anticancer Res (2007) 0.75